Phesgo
Active Ingredient(s): Pertuzumab + Trastuzumab + Hyaluronidase-zzxfFDA Approved: * June 29, 2020
Pharm Company: * GENENTECH INC
Category: Cancer
Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer.[3][4] It contains pertuzumab, trastuzumab, and hyaluronidase–zzxf.[3] It is injected under the skin via subcutaneous injection in the thigh.[3] In the Euro... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.